Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era
Abstract
Historically, African American (AA) patients with renal cell carcinoma (RCC) have had inferior survival compared with Caucasian patients. Recent studies suggest that the survival disparity between races may be worsening since the advent of targeted therapies for RCC. In this study, survival rates among AA and Caucasian patients with advanced RCC are examined over time to determine whether a disparity in survival persists in the targeted therapy era.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 24, 2016
- Source ID
- 10.1002/cncr.30146
Entities
People
- Allison M. Deal
- Angela B. Smith
- Bhavani Krishnan
- Matthew E. Nielsen
- Matthew I. Milowsky
- Tracy L. Rose
- William Y. Kim
Organizations
- American Association for Cancer Research
- American Cancer Society
- National Center for Advancing Translational Sciences
- National Center for Research Resources
- National Institutes of Health
- Patient-Centered Outcomes Research Institute
- United States Department of Defense
- University of North Carolina at Chapel Hill